en
svPress releases
Regulatory press release 2021-10-25
Xspray Pharma brings forward publication of the Q3 interim report
Regulatory press release 2021-10-15
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022
Regulatory press release 2021-10-13
Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™
Regulatory press release 2021-08-06
Xspray Pharma publishes interim report Q2 , January – June 2021
Regulatory press release 2021-07-28
Xspray Pharma announces achievement of bioequivalence compared with reference product from bioequivalence study with HyNap-Dasa 505(b)(2)
Regulatory press release 2021-05-20
Bulletin from the annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2021-05-06
Xspray Pharma publishes Interim Report Q1, January – March 2021
Regulatory press release 2021-04-20
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2021-04-08
Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA)
Regulatory press release 2021-03-19